Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Tyzivumab in healthy volunteers
NCT03443830Phase 1Completed
- Sponsor
- Tychan
- Start
- Feb 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tyzivumab in Zika virus infection (6 cohorts), sponsored by Tychan. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 84 days. Started Feb 2018; status: completed.
02
Drugs
tyzivumab
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03443830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443830.